Originally posted on 5/29/2013
ASAP Corporate Members Astellas and Amgen announced that the two companies will be forming a joint venture later this year
called Amgen Astellas BioPharma KK that is focused on serving patients in Japan.
It's a classic alliance situation. As is usually the case, Amgen needs some on-the-ground expertise to navigate the particulars of a foreign country. Thus, the two companies will collaborate on five of Amgen's drug candidates with Astellas providing the insights into Japan's health care landscape.
This collaboration appears to be a major investment for both sides. It will cover clinical- and commercial-phase drugs, and employees from both companies will be collocated together along with new employees specifically hired for this venture.